Prospective Research Rare Kidney Stones


About this study

The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. Cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of primary hyperoxaluria
  • Diagnosis of enteric hyperoxaluria
  • Diagnosis of Dent Disease
  • Diagnosis of Cystinuria
  • Diagnosis of adenine phosphoribosyltransferase deficiency (APRTd)
  • Diagnosis of Lowe Syndrome
  • Diagnosis of Dent Disease Carrier

Exclusion Criteria:

  • Prior renal failure
  • History of liver and/or kidney transplant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

William Haley, M.D.

Open for enrollment

Contact information:

Mayo Clinic Hyperoxaluria Center

(800) 270-4637

More information


Publications are currently not available

Mayo Clinic Footer